Potential use of psilocybin drugs in the treatment of depression
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, Andrzej Pilc
Expert Opinion on Emerging Drugs October 2, 2023 DOI: 10.1080/14728214.2023.2264180 via OpenAlex
Summary
AI-generated from the abstractPsilocybin shows promise in early clinical trials for treating major depressive disorder and treatment-resistant depression, with effects appearing relatively quickly after administration. However, large phase III trials are still needed to confirm its efficacy and safety before it can be approved and accepted by physicians and patients.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Anxiety Depression Psilocybin Psychedelic-assisted therapy |
| Keywords | Psychedelics Mental health Depression treatment |
| Citations | 4 |
| Key finding | Psilocybin has shown promising results in phase I-II trials for depression, but phase III trials are required to confirm efficacy and safety. |
Abstract
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to confirm its efficacy and safety and to change the way it is perceived by physicians and patients.